Stryker (SYK) Getting Somewhat Favorable News Coverage, Analysis Finds
News headlines about Stryker (NYSE:SYK) have trended somewhat positive on Wednesday, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Stryker earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news stories about the medical technology company an impact score of 46.9357017085682 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media headlines that may have effected Accern’s scoring:
- Stryker almost there in takeover of Vexim (seekingalpha.com)
- Stryker crosses the 95% thresholds in VEXIM and announces its intention to file a proposed public buy-out offer followed by a squeeze-out for the outstanding shares of VEXIM (finance.yahoo.com)
- Tracking Yacktman Asset Management Portfolio – Q4 2017 Update (seekingalpha.com)
- Quotidian Technical Highlights on Selected Medical Equipment Stocks — ReShape Lifesciences, Smith & Nephew, Stryker, and Zimmer Biomet (prnewswire.com)
- Stryker Corporation to Post Q3 2018 Earnings of $1.66 Per Share, SunTrust Banks Forecasts (SYK) (americanbankingnews.com)
Several equities analysts recently commented on SYK shares. Zacks Investment Research upgraded shares of Stryker from a “sell” rating to a “hold” rating in a report on Tuesday, October 24th. Robert W. Baird reiterated a “hold” rating and set a $161.00 price target on shares of Stryker in a report on Friday, October 27th. Piper Jaffray Companies reiterated a “buy” rating and set a $156.00 price target on shares of Stryker in a report on Friday, October 27th. Wells Fargo & Co upped their price target on shares of Stryker from $160.00 to $166.00 in a report on Friday, October 27th. Finally, Stifel Nicolaus upped their price target on shares of Stryker from $158.00 to $168.00 and gave the company a “buy” rating in a report on Friday, October 27th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $162.50.
Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.01. The company had revenue of $3.47 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.78 EPS. research analysts predict that Stryker will post 7.12 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be given a $0.47 dividend. The ex-dividend date is Wednesday, March 28th. This represents a $1.88 annualized dividend and a yield of 1.20%. Stryker’s dividend payout ratio (DPR) is 70.15%.
In other news, Director Howard E. Cox, Jr. sold 7,400 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $164.09, for a total value of $1,214,266.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP William E. Berry, Jr. sold 1,306 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $164.42, for a total transaction of $214,732.52. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,840 shares of company stock valued at $2,749,989. 7.40% of the stock is owned by corporate insiders.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.